BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tanaka M, Vécsei L. Monitoring the Redox Status in Multiple Sclerosis. Biomedicines 2020;8:E406. [PMID: 33053739 DOI: 10.3390/biomedicines8100406] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Kahroba H, Ramezani B, Maadi H, Sadeghi MR, Jaberie H, Ramezani F. The role of Nrf2 in neural stem/progenitors cells: From maintaining stemness and self-renewal to promoting differentiation capability and facilitating therapeutic application in neurodegenerative disease. Ageing Res Rev 2021;65:101211. [PMID: 33186670 DOI: 10.1016/j.arr.2020.101211] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 26.0] [Reference Citation Analysis]
2 Díaz M, Mesa-Herrera F, Marín R. DHA and Its Elaborated Modulation of Antioxidant Defenses of the Brain: Implications in Aging and AD Neurodegeneration. Antioxidants (Basel) 2021;10:907. [PMID: 34205196 DOI: 10.3390/antiox10060907] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Ermakov EA, Melamud MM, Buneva VN, Ivanova SA. Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives. Front Psychiatry 2022;13:880568. [PMID: 35546942 DOI: 10.3389/fpsyt.2022.880568] [Reference Citation Analysis]
4 Behl T, Kaur I, Sehgal A, Singh S, Bhatia S, Al-Harrasi A, Zengin G, Bumbu AG, Andronie-Cioara FL, Nechifor AC, Gitea D, Bungau AF, Toma MM, Bungau SG. The Footprint of Kynurenine Pathway in Neurodegeneration: Janus-Faced Role in Parkinson's Disorder and Therapeutic Implications. Int J Mol Sci 2021;22:6737. [PMID: 34201647 DOI: 10.3390/ijms22136737] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Török N, Tanaka M, Vécsei L. Searching for Peripheral Biomarkers in Neurodegenerative Diseases: The Tryptophan-Kynurenine Metabolic Pathway. Int J Mol Sci 2020;21:E9338. [PMID: 33302404 DOI: 10.3390/ijms21249338] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
6 Boziki M, Bakirtzis C, Sintila SA, Kesidou E, Gounari E, Ioakimidou A, Tsavdaridou V, Skoura L, Fylaktou A, Nikolaidou V, Stangou M, Nikolaidis I, Giantzi V, Karafoulidou E, Theotokis P, Grigoriadis N. Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response. Cells 2022;11:1959. [PMID: 35741088 DOI: 10.3390/cells11121959] [Reference Citation Analysis]
7 Immovilli P, Morelli N, Terracciano C, Rota E, Marchesi E, Vollaro S, De Mitri P, Zaino D, Bazzurri V, Guidetti D. Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach. Neurol Int 2022;14:368-77. [PMID: 35466211 DOI: 10.3390/neurolint14020030] [Reference Citation Analysis]
8 Duarte-Jurado AP, Gopar-Cuevas Y, Saucedo-Cardenas O, Loera-Arias MJ, Montes-de-Oca-Luna R, Garcia-Garcia A, Rodriguez-Rocha H. Antioxidant Therapeutics in Parkinson's Disease: Current Challenges and Opportunities. Antioxidants (Basel) 2021;10:453. [PMID: 33803945 DOI: 10.3390/antiox10030453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
9 Tanaka M, Tóth F, Polyák H, Szabó Á, Mándi Y, Vécsei L. Immune Influencers in Action: Metabolites and Enzymes of the Tryptophan-Kynurenine Metabolic Pathway. Biomedicines 2021;9:734. [PMID: 34202246 DOI: 10.3390/biomedicines9070734] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Pires AS, Sundaram G, Heng B, Krishnamurthy S, Brew BJ, Guillemin GJ. Recent advances in clinical trials targeting the kynurenine pathway. Pharmacol Ther 2021;:108055. [PMID: 34929198 DOI: 10.1016/j.pharmthera.2021.108055] [Reference Citation Analysis]
11 Verma V, Singh D, Kh R. Sinapic Acid Alleviates Oxidative Stress and Neuro-Inflammatory Changes in Sporadic Model of Alzheimer's Disease in Rats. Brain Sci 2020;10:E923. [PMID: 33266113 DOI: 10.3390/brainsci10120923] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
12 Chobot V, Hadacek F, Bachmann G, Weckwerth W, Kubicova L. In Vitro Evaluation of Pro- and Antioxidant Effects of Flavonoid Tricetin in Comparison to Myricetin. Molecules 2020;25:E5850. [PMID: 33322312 DOI: 10.3390/molecules25245850] [Reference Citation Analysis]
13 Malla B, Liotta A, Bros H, Ulshöfer R, Paul F, Hauser AE, Niesner R, Infante-Duarte C. Teriflunomide Preserves Neuronal Activity and Protects Mitochondria in Brain Slices Exposed to Oxidative Stress. Int J Mol Sci 2022;23:1538. [PMID: 35163469 DOI: 10.3390/ijms23031538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Tanaka M, Török N, Tóth F, Szabó Á, Vécsei L. Co-Players in Chronic Pain: Neuroinflammation and the Tryptophan-Kynurenine Metabolic Pathway. Biomedicines 2021;9:897. [PMID: 34440101 DOI: 10.3390/biomedicines9080897] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Quirant-Sánchez B, Mansilla MJ, Navarro-Barriuso J, Presas-Rodríguez S, Teniente-Serra A, Fondelli F, Ramo-Tello C, Martínez-Cáceres E. Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosis. Biomedicines 2021;9:1758. [PMID: 34944573 DOI: 10.3390/biomedicines9121758] [Reference Citation Analysis]
16 Signorile A, Ferretta A, Ruggieri M, Paolicelli D, Lattanzio P, Trojano M, De Rasmo D. Mitochondria, Oxidative Stress, cAMP Signalling and Apoptosis: A Crossroads in Lymphocytes of Multiple Sclerosis, a Possible Role of Nutraceutics. Antioxidants (Basel) 2020;10:E21. [PMID: 33379309 DOI: 10.3390/antiox10010021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Burgetova A, Dusek P, Uher T, Vaneckova M, Vejrazka M, Burgetova R, Horakova D, Srpova B, Krasensky J, Lambert L. Oxidative Stress Markers in Cerebrospinal Fluid of Newly Diagnosed Multiple Sclerosis Patients and Their Link to Iron Deposition and Atrophy. Diagnostics 2022;12:1365. [DOI: 10.3390/diagnostics12061365] [Reference Citation Analysis]
18 Luca M, Chisari CG, Zanghì A, Patti F. Early-Onset Alcohol Dependence and Multiple Sclerosis: Diagnostic Challenges. Int J Environ Res Public Health 2021;18:5588. [PMID: 34073738 DOI: 10.3390/ijerph18115588] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Diez-Iriepa D, Chamorro B, Talaván M, Chioua M, Iriepa I, Hadjipavlou-Litina D, López-Muñoz F, Marco-Contelles J, Oset-Gasque MJ. Homo-Tris-Nitrones Derived from α-Phenyl-N-tert-butylnitrone: Synthesis, Neuroprotection and Antioxidant Properties. Int J Mol Sci 2020;21:E7949. [PMID: 33114714 DOI: 10.3390/ijms21217949] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Sandi D, Kokas Z, Biernacki T, Bencsik K, Klivényi P, Vécsei L. Proteomics in Multiple Sclerosis: The Perspective of the Clinician. Int J Mol Sci 2022;23:5162. [PMID: 35563559 DOI: 10.3390/ijms23095162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Tanaka M, Vécsei L. Editorial of Special Issue "Crosstalk between Depression, Anxiety, and Dementia: Comorbidity in Behavioral Neurology and Neuropsychiatry". Biomedicines 2021;9:517. [PMID: 34066395 DOI: 10.3390/biomedicines9050517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Al-falaki TA, Hamdan FB, Sheaheed NM. Assessment of cognitive functions in patients with multiple sclerosis. Egypt J Neurol Psychiatry Neurosurg 2021;57. [DOI: 10.1186/s41983-021-00383-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Tóth F, Cseh EK, Vécsei L. Natural Molecules and Neuroprotection: Kynurenic Acid, Pantethine and α-Lipoic Acid. Int J Mol Sci 2021;22:E403. [PMID: 33401674 DOI: 10.3390/ijms22010403] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
24 Zarzuelo-Romero MJ, Pérez-Ramírez C, Cura Y, Carrasco-Campos MI, Marangoni-Iglecias LM, Ramírez-Tortosa MC, Jiménez-Morales A. Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate in Multiple Sclerosis Patients. J Pers Med 2021;11:1032. [PMID: 34683173 DOI: 10.3390/jpm11101032] [Reference Citation Analysis]
25 Mor A, Tankiewicz-Kwedlo A, Krupa A, Pawlak D. Role of Kynurenine Pathway in Oxidative Stress during Neurodegenerative Disorders. Cells 2021;10:1603. [PMID: 34206739 DOI: 10.3390/cells10071603] [Reference Citation Analysis]
26 Arslan B, Arslan GA, Tuncer A, Karabudak R, Dinçel AS. Evaluation of Thiol Homeostasis in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Front Neurol 2021;12:716195. [PMID: 34526962 DOI: 10.3389/fneur.2021.716195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Lopresti P. Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis. Biomedicines 2022;10:1077. [DOI: 10.3390/biomedicines10051077] [Reference Citation Analysis]
28 Carta MG, Kalcev G, Fornaro M, Nardi AE. Novel experimental and early investigational drugs for the treatment of bipolar disorder. Expert Opin Investig Drugs 2021;30:1081-7. [PMID: 34844484 DOI: 10.1080/13543784.2021.2000965] [Reference Citation Analysis]
29 Longoria V, Parcel H, Toma B, Minhas A, Zeine R. Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination. Biomedicines 2022;10:539. [DOI: 10.3390/biomedicines10030539] [Reference Citation Analysis]